Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 3103-3108

  Skarlos, Dimosthenis V ^a   Kalofonos, Haralabos P ^b   Fountzilas, George ^c   Dimopoulos, Meletios A ^d   Pavlidis, Nicholas ^e   Razis, Evangelia ^f   Economopoulos, Theofanis ^g   Pectasides, Dimitrios ^g   Gogas, Helen ^h   Kosmidis, Paris ^f   Bafaloukos, Dimitrios ⁱ   Klouvas, George ^a   Kyratzis, George ^j   Aravantinos, Gerasimos ^j  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f HYGEIA HOSPITAL   (Greece)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h LAIKO GENERAL HOSPITAL   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j AGII ANARGIRI CANCER HOSPITAL   (Greece)

more..

Author keywords

Gemcitabine; Ovarian cancer; Pegylated liposomal doxorubicin

Indexed keywords

DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGRANULOCYTOSIS; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG RESISTANCE; DRUG RESPONSE; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LUNG INJURY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DEFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TAXOIDS;

EID: 22944470084     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Berek JS, Bertelsen A, du Bois A et al: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10(suppl. 1): 87-92, 1999.
2. Ozols RF, Schwartz PE and Eifel PJ: Ovarian cancer, falopian tube carcinoma, and peritoneal carcinoma. In: De Vita Vr Jr, Hellman S, Rosenberg SA (eds.). Cancer: Principles and Practice of Oncology, Sixth Edition, Philadelphia: Lippincot Williams and Wilkins, pp. 1597-1632, 2001.
3. Mc Guire WP, Hoskins WJ, Mark F et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1995.
4. Markman M and Bookman MA: Second-line treatment of ovarian cancer. Oncologist 5: 26-35, 2000.
5. Armstrong DA: Relapsed ovarian cancer - challenges and management strategies for a chronic disease. Oncologist 7(suppl 5): 20-28, 2002.
6. Markman M, Rothman R, Hakes T et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
7. Vergote I, Himmaelmann A, Frankendal B et al: Hexmethyl-melamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47: 282-286, 1992.
8. Hoskins PJ and Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12: 60-63, 1994.
9. Sutton GP, Blessing JA, Homosley HD et al: Phase II trial of ifosphamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7: 1672-1676, 1989.
10. Bajetta E, Di Leo A, Biganzoli L et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14: 2546-2551, 1996.
11. Herzog TJ: Update on the role of topotecan of recurrent ovarian cancer. J Clin Oncol 16: 2233-2237, 1998.
12. Shappiro JD, Millward MJ, Rischin D et al: Activity of gemcitabine in patients with advanced ovarian cancer. Responses seen following platimum and paclitaxel. Gynecol Oncol 63: 89-93, 1996.
13. Aravantinos G, Dimopoulos MA, Kosmidis P et al: Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol 11: 607-612, 2000.
14. Aravantinos G, Bafaloukos D, Fountzilas G et al: Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14: 1094-1099, 2003.
15. Plunkett W, Huang P, Xu YZ et al: Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin Oncol 22(4): 3-10, 1995.
16. Plunkett W, Huang P, Searcy CE et al: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(suppl 10): 3-15, 1996.
17. Hong RL and Tseng YL: Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 97(9): 1826-1833, 2001.
18. Muggia FM, Hainsworth JD, Jeffers S et al: Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093-3100, 2000.
19. Gordon AN, Fleagle JT, Guthrie D et al: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322; 2001.
20. Smith DH, Adams JR, Johnston SRD et al: A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and UK. Ann Oncol 13: 1579-1590, 2002.
21. Ojeda B, de Sante LM, Casado A et al: Cost-minimization analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 89: 1002-1007, 2003.
22. Capri S and Cattaneo J: Cost minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clin Therap 25(6): 1826-1845, 2003.
23. Machin D: Sample Size Tables for Clinical Studies (second edition). Blackwell Science, pp. 285-286, 1997.
24. Kaplan E and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
25. Lentner C: Geigy Scientific Tables. Ciba-Geigy, Switzerland, 1982 (Exact confidence limits for p, pp. 89-102).
26. Tobias D, Astrow A, Koulos J et al: A phase I trial of gemcitabine and doxil for recurrent epithelial cancer. Proc Am Soc Clin Oncol 19: A1551, 2000.
27. Horwood K, Colosimo M, Wyld D et al: A phase II trial of gemcitabine and liposomal doxorubicin in platinum-resistant ovarian cancer. Proc Ann Soc Clin Oncol 21: A 888, 2002.
28. D'Agostino G, Ferrandina G, Garganese G et al: Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 62(2): 110-114, 2002.
29. D'Agostino G, Ludovisi M, Ferrandina G et al: The liposomal doxorubicin (CAE) and gemcitabine (GEM) combination is active in relapsed ovarian cancer: a phase II study. Proc Am Soc Clin Oncol 21: A875-877, 2002.